Determining the Dual Effect of Mirabegron on Anticancer Mechanism and Brown Adipose Tissue Activation - An in-silico Approach

Mirabegron, a 3-adrenoceptor agonist first developed for treating overactive bladder, has shown unexpected impacts on cancer and metabolic processes.Initially targeting the bladder's detrusor muscle, new research has revealed its potential in cancer therapy and brown adipose tissue (BAT) activation.This work employs silico approaches to evaluate how Mirabegron impacts critical cellular pathways such as AMPK, mTOR, and UCP, which are important for cancer and metabolic regulation.Docking studies show that Mirabegron binds effectively to several targets, with high affinities indicating a meaningful interaction.Specifically, it binds to AMPK at -7.0 kcal/mol, mTOR at -5.4 kcal/mol, and UCP at -7.4 kcal/mol.These interactions contain key residues, indicating that Mirabegron's influence extends beyond its original usage, potentially affecting cancer progression and metabolism.